Medical device with drug

Abstract

A method of coating implantable open lattice metallic stent prosthesis is disclosed which includes sequentially applying a plurality of relatively thin outer layers of a coating composition comprising a solvent mixture of uncured polymeric silicone material and crosslinker and finely divided biologically active species, possibly of controlled average particle size, to form a coating on each stent surface. The coatings are cured in situ and the coated, cured prosthesis are sterilized in a step that includes preferred pretreatment with argon gas plasma and exposure to gamma radiation electron beam, ethylene oxide, steam.

Description

I. CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application is a Continuation-In-Part of copending application Ser. No. 08 / 526,273, filed Sep. 11, 1995, and a Continuation-In-Part of copending application Ser. No. 08 / 424,884, filed Apr. 19, 1995, all portions of the parent applications not contained in this application being deemed incorporated by reference for any purpose. Cross-reference is also made to application Ser. No. 08 / ______, entitled “DRUG RELEASE STENT COATING AND PROCESS”, filed of even date and of common inventorship and assignee, that is also a Continuation-In-Part of both above-referenced patent applications. Any portion of that application that is not contained herein is also deemed to be incorporated by reference for any purpose.BACKGROUND OF THE INVENTION [0002] II. Field of the Invention [0003] The present invention relates generally to therapeutic expandable stent prosthesis for implantation in body lumens, e.g., vascular implantation and, more pa...

AI Technical Summary

Benefits of technology

[0030] The desired release rate profile can be tailored by varying the coating thickness, the radial distribution (layer to layer) of bioactive materials, the mixing method, the amount of bioactive material, the combination of different matrix polymer materials at different layers, and the crosslink density of the polymeric material. The crosslink density is related to the amount of crosslinking which takes place and also the relative tightness of the matrix created by the particular crosslinking agent used. This, during the curing process, determines the amount of crosslinking and so the crosslink density of the polymer material. For bioactive materials released from the crosslinked matrix, such as heparin, a crosslink structure of greater density will increase release time and reduce burst effect.

[0031] Additionally, with eluting materials such as heparin, release kinetics, particularly initial drug release rate, can be affected by varying the average dispersed particle size. The observed initial release rate or burst effect may be substantially reduced by using smaller particles, particularly if the particle size is controlled to be less than about 15 microns and the effect is even more significant in the particle size range of ≦10 microns, especially when the coating thickness is not more than about 50 μm and drug loading is about 25-45 weight percent.

[0032] It will also be appreciated that an unmedicated silicone thin top layer provides an advantage over drug containing top coat. Its surface has a limited porosity and is generally smooth, which may be less thrombogeneous and may reduce the chance to develop calcification, which occurs most often on the porous surface.

Problems solved by technology

This, in turn, reduces the cross-sectional area available for flow through the stent and / or reduces the relative amount of open space available in the structure.

In addition, when applicable, it is usually more difficult to load and deliver polymeric stents using vascular catheter delivery systems.

Images